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Background
The ovalbumin (OVA) sensitized and challenged Brown
Norway (BN) rat model is a practical PD model often
used to determine the impact of drug treatment on late
phase lung inflammation. However, the sole measurement
of bronchoalveolar lavage fluid (BALF) inflammatory cells
does not always correlate into human efficacy for respira-
tory diseases such as asthma. Added value to this rodent
model may be derived by a deeper understanding of the
relationship between disease-related cytokine secretion
and inflammation.
Materials and methods
Animal sensitizations, challenges, and BALF collections
were performed as described previously [1]. Inflammatory
cell counts and cytokine temporal profile was investigated
in BALF samples collected from animals at 6, 24, 48, and
72 hours post whole-body OVA challenge. Effect of orally
dosed betamethasone on the temporal profile of inflam-
matory cells and cytokines was also investigated.
Results
Differential cell counts from BALF showed an increase
in neutrophil levels at 6h, reaching maximum at 24h, in
OVA challenged animals. The influx of eosinophils in
BALF continues to increase with time, reaching peak at
72h. Baseline levels for a panel of cytokines (including
IL-13 and IL-5) were also established with most reaching
maximal levels at 24h. A significant inhibition of neutro-
phil levels was seen in the betamethasone group at 6h
(71%) and 24h (67%) along with inhibition of IL-13 (90 %)
at 24h. Betamethasone was also able to significantly inhibit
eosinophilia and IL-13 at 48h time point.
Conclusions
We were able to confirm the temporal profile of cytokine
secretion in BALF in this model. In addition, we have
shown that betamethasone inhibited both cytokines and
cell infiltration in a dose dependent manner. The cytokine
endpoint in conjunction with cell influx brings added
value to the standard OVA challenged Brown Norway rat
model.
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